Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iridex Corp (NQ: IRIX )

2.016 -0.014 (-0.70%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,309
Open 2.030
Bid (Size) 1.970 (2)
Ask (Size) 2.020 (6)
Prev. Close 2.030
Today's Range 1.970 - 2.030
52wk Range 1.310 - 3.650
Shares Outstanding 16,007,161
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IRIX Stock Earnings: Iridex Misses EPS, Misses Revenue for Q1 2024
IRIX stock results show that Iridex missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

YTD
-29.76%
-29.76%
1 Month
-4.46%
-4.46%
3 Month
-41.57%
-41.57%
6 Month
-34.76%
-34.76%
1 Year
-1.67%
-1.67%

More News

Read More
Iridex Reports First Quarter 2024 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
From IRIDEX Corporation
Via GlobeNewswire
Iridex: Q4 Earnings Insights
Via Benzinga
Iridex's Earnings Outlook
Via Benzinga
Iridex: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
IRIX Stock Earnings: Iridex Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
From IRIDEX Corporation
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
From IRIDEX Corporation
Via GlobeNewswire
Iridex Corporation Receives European Patent on MicroPulse Technology
From IRIDEX Corporation
Via GlobeNewswire
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
From IRIDEX Corporation
Via GlobeNewswire
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
From IRIDEX Corporation
Via GlobeNewswire
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
From IRIDEX Corporation
Via GlobeNewswire
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
From IRIDEX Corporation
Via GlobeNewswire
Iridex Reports Third Quarter 2023 Financial Results and Business Update
From IRIDEX Corporation
Via GlobeNewswire
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
From IRIDEX Corporation
Via GlobeNewswire
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.